A 52-year-old woman with a history of dilated cardiomyopathy (EF 28%) and recurrent syncope presents to the outpatient clinic. She is on optimal medical therapy (ACE inhibitor, beta-blocker, aldosterone antagonist) but continues to have non-sustained ventricular tachycardia on Holter monitoring (runs of 5–8 beats at 150 bpm). She is awaiting an ICD but it is not yet available. What is the most appropriate additional pharmacological therapy to reduce sudden cardiac death risk?

Explanation

## Prevention of Sudden Cardiac Death in Dilated Cardiomyopathy with NSVT ### Clinical Context **Key Point:** Non-sustained VT (NSVT) in a patient with reduced ejection fraction (EF 28%) and syncope is a strong predictor of sudden cardiac death. ICD is the gold standard, but while awaiting implantation, amiodarone is the only antiarrhythmic with proven mortality benefit in this population. ### Antiarrhythmic Drug Comparison in Reduced EF | Drug | Class | EF ≤35% Safety | Mortality Benefit | SCD Prevention | Notes | |------|-------|---|---|---|---| | **Amiodarone** | I, II, III, IV | Safe | Yes (GESICA, CHF-STAT) | Excellent | First-line for HF + NSVT | | Sotalol | II, III | Caution | No | Moderate | Risk of torsades; less effective than amiodarone | | Flecainide | I | **Contraindicated** | No | Poor | CAST trial: ↑ mortality in CAD + reduced EF | | Digoxin | IV | Safe | No | Poor | No SCD prevention; inotropic only | **High-Yield:** The CAST trial (1989) showed that flecainide and encainide increased mortality in post-MI patients with reduced EF, even though they suppressed arrhythmias. This principle applies to all Class I agents in structural heart disease. ### Amiodarone Evidence ```mermaid flowchart TD A[Reduced EF + NSVT + Syncope]:::outcome --> B[ICD indicated]:::action B --> C{ICD available?}:::decision C -->|Yes| D[Implant ICD]:::action C -->|No - Awaiting| E[Bridge with Amiodarone]:::action E --> F[200 mg daily]:::action F --> G[Reduces arrhythmia burden]:::outcome F --> H[Reduces SCD risk while awaiting ICD]:::outcome ``` **Clinical Pearl:** Amiodarone works in HF because it: - Blocks all four Vaughan-Williams classes (I, II, III, IV) - Has negative inotropic effect BUT increases systemic vascular resistance - Does NOT increase mortality in HF (unlike Class I agents) - Reduces both VT/VF episodes and all-cause mortality **Mnemonic:** **AMIO** — Antiarrhythmic of choice; Mortality benefit proven; ICD bridge therapy; Only Class I agent safe in reduced EF. ### Why Not Sotalol? **Warning:** Although sotalol is a Class II/III agent (safer than Class I), it: - Lacks mortality benefit in HF with reduced EF - Carries risk of torsades de pointes (Class III effect) - Is less effective than amiodarone for NSVT suppression - Should not be used as monotherapy in EF ≤35% [cite:Harrison 21e Ch 226; Braunwald's Heart Disease 12e Ch 37]